PURPOSE-An animal model of pancreatic cancer that is large enough to permit imaging and catheterization would be desirable for interventional radiologists to develop novel therapies for pancreatic cancer. The purpose of this study was to test the hypothesis that the VX2 rabbit model of pancreatic cancer could be developed as a suitable platform to test future interventional therapies.
MATERIALS AND METHODS-The authors implanted and grew three pancreatic VX2 tumors per rabbit in six rabbits. Magnetic resonance (MR) imaging was performed at two weeks to confirm tumor growth. At three weeks, the authors selectively catheterized the gastroduodenal artery under guidance of x-ray digital subtraction angiography (DSA). T2-weighted anatomic, diffusion-weighted (DWI), and transcatheter intraarterial perfusion (TRIP) MR imaging were then performed. Following imaging, tumors were confirmed at necropsy and histopathology. Size of tumors at two and three weeks was compared using a paired t-test (P = .05).RESULTS-VX2 pancreatic tumors were grown in 6/6 rabbits. The difference between tumor size at two and three weeks, 1.29 cm (± 0.39) and 1.91 cm (±0.50) respectively, was statistically significant (p < .001). All tumors were confirmed to be located within pancreatic tissue via histopathology. DSA, TRIP MR, DWI and anatomic MR imaging was successful in 5/6 rabbits. DWI and anatomic MR imaging was successful in 6/6 rabbits.CONCLUSION-The VX2 rabbit model of pancreatic cancer is feasible, as verified by imaging and pathologic correlation, and may be a suitable platform to test future interventional therapies.